세계의 주사기 및 주사제 포장 시장 : 기회, 촉진요인, 업계 동향 분석, 예측(2025-2034년)

The Global Syringes and Injectable Drugs Packaging Market was valued at USD 30.6 billion in 2024 and is estimated to grow at a CAGR of 13.3% to reach USD 105.9 billion by 2034, driven by the rising demand for injectable therapies, especially amid increasing cases of chronic and infectious diseases. The healthcare industry is experiencing a rapid shift toward injectable drug delivery due to its ability to provide fast-acting relief and precise dosing. This shift is reshaping the pharmaceutical packaging landscape, pushing manufacturers to innovate and adapt to evolving medical needs. The surge in minimally invasive treatments, expansion of biologics, and growing preference for self-administered drugs are reinforcing the critical role of advanced packaging systems. As pharmaceutical companies continue to expand their injectable portfolios, the demand for packaging that ensures sterility, ease of use, and regulatory compliance is becoming more urgent than ever. Moreover, global health crises and aging populations are further intensifying the need for effective, safe, and scalable drug delivery solutions, particularly in emergency, ambulatory, and home-based care settings.

The increasing use of injectables for quick drug administration, especially in outpatient and emergency care, has created a heightened need for secure, sterile packaging that upholds drug integrity and patient safety. Ensuring the packaging of syringes and injectable drugs meets strict safety standards is essential to prevent contamination, maintain drug stability, and comply with healthcare regulations across clinical settings.

Despite its rapid growth, the market is facing notable challenges. Shifting trade policies and tariffs on medical components are complicating pricing structures and limiting product availability. Recent tariff hikes on imported materials have driven up manufacturing costs, especially for sterile injectables and low-cost therapies where affordability is critical. Industry players are responding by stockpiling raw materials and pushing for phased policy shifts, but supply chain disruptions remain a significant hurdle for manufacturers aiming to meet rising demand without compromising quality or cost-efficiency.

Based on product type, the market is segmented into syringes and packaging formats tailored to injectable drugs. Syringes alone are expected to generate USD 54.2 billion by 2034 as hospitals, clinics, and home care settings increasingly adopt pre-sterilized, tamper-evident solutions to reduce contamination risks and enhance drug delivery safety. The expanding use of injectable therapies across vaccines, diabetes, and autoimmune diseases is also driving the adoption of single-use, safety-enhanced syringe systems.

In terms of material, the market includes plastic, glass, and other specialized substrates. Plastic is projected to lead with an estimated market size of USD 42.5 billion by 2034 due to its lightweight, break-resistant, and affordable properties. Plastic is the material of choice for prefilled syringes and self-injection devices, supporting designs with integrated safety features like retractable needles and dose-tracking systems.

North America held a 39% market share in 2024 and continues to dominate, thanks to its strong pharmaceutical manufacturing infrastructure and advanced healthcare systems. The demand for prefilled and disposable injectable packaging is rising fast as hospitals and home care providers seek to reduce infection rates and streamline drug administration.

Leading companies, including Nipro Europe Group Companies, Gerresheimer, West Pharmaceutical Services, Inc., Schott AG, and BD, are investing in R&D, expanding manufacturing footprints, automating production lines, and building strategic partnerships to improve product safety, boost production efficiency, and maintain regulatory compliance across global markets.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Trump administration tariffs
  • 3.2.1 Impact on trade
    • 3.2.1.1 Trade volume disruptions
    • 3.2.1.2 Retaliatory measures
  • 3.2.2 Impact on the industry
    • 3.2.2.1 Supply-side impact (raw materials)
      • 3.2.2.1.1 Price volatility in key materials
      • 3.2.2.1.2 Supply chain restructuring
      • 3.2.2.1.3 Production cost implications
    • 3.2.2.2 Demand-side impact (selling price)
      • 3.2.2.2.1 Price transmission to end markets
      • 3.2.2.2.2 Market share dynamics
      • 3.2.2.2.3 Consumer response patterns
  • 3.2.3 Key companies impacted
  • 3.2.4 Strategic industry responses
    • 3.2.4.1 Supply chain reconfiguration
    • 3.2.4.2 Pricing and product strategies
    • 3.2.4.3 Policy engagement
  • 3.2.5 Outlook and future considerations
• 3.3 Industry impact forces
  • 3.3.1 Growth drivers
    • 3.3.1.1 Increased demand for injectable drug delivery
    • 3.3.1.2 Growth in consumer vaccination and other drugs
    • 3.3.1.3 Technological advancements in packaging
    • 3.3.1.4 Sustainability and environmental pressures
    • 3.3.1.5 Aging population and increasing global healthcare access
  • 3.3.2 Industry pitfalls and challenges
    • 3.3.2.1 Device compatibility and drug stability issues
    • 3.3.2.2 Raw material supply constraints
• 3.4 Growth potential analysis
• 3.5 Regulatory landscape
• 3.6 Technology landscape
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates & Forecast, By Product Type, 2021 - 2034 (USD Billion)

• 5.1 Key trends
• 5.2 Syringes
  • 5.2.1 Prefilled syringes
  • 5.2.2 Conventional syringes
• 5.3 Injectable drugs packaging
  • 5.3.1 Vials
  • 5.3.2 Ampoules
  • 5.3.3 Cartridges
  • 5.3.4 Bottles

Chapter 6 Market Estimates & Forecast, By Material Type, 2021 - 2034 (USD Billion)

• 6.1 Key trends
• 6.2 Plastic
  • 6.2.1 Polypropylene (PP)
  • 6.2.2 Polyethylene (PE)
  • 6.2.3 Polycarbonate (PC)
  • 6.2.4 Others
• 6.3 Glass
• 6.4 Others

Chapter 7 Market Estimates & Forecast, By End Use, 2021 - 2034 (USD Billion)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Ambulatory surgical centers (ASCs)
• 7.4 Pharmaceutical & biotechnology companies
• 7.5 Home healthcare settings
• 7.6 Vaccination centers

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 (USD Billion)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 BD
• 9.2 AptarGroup, Inc.
• 9.3 Bormioli Pharma S.p.A.
• 9.4 Catalent, Inc
• 9.5 Credence MedSystems, Inc.
• 9.6 DWK Life Sciences.
• 9.7 Gerresheimer
• 9.8 J.Penner Corporation
• 9.9 Laboratorios Farmaceuticos Rovi S.A.
• 9.10 Nipro Europe Group Companies
• 9.11 Schott AG
• 9.12 SGD Pharma
• 9.13 Shandong Province Medicinal Glass Co., Ltd.
• 9.14 Stevanato Group
• 9.15 Terumo Europe NV
• 9.16 USIN Advance Co., Ltd.
• 9.17 Weigao Group
• 9.18 West Pharmaceutical Services, Inc.